Announcement • Jul 16
Avaí Bio, Inc. Auditor Raises 'Going Concern' Doubt Avaí Bio, Inc. filed its Annual on Jul 14, 2026 for the period ending Mar 31, 2026. In this report its auditor, DylanFloyd Accounting & Consulting, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Announcement • Jul 01
Avaí Bio, Inc. announced delayed annual 10-K filing On 06/30/2026, Avaí Bio, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Apr 11
Avaí Bio, Inc. Presents Latest Data on ?-Klotho Anti-Aging Therapy and Advances Cell-Based Therapies For most of modern biology, aging has been treated as a backdrop — the inevitable canvas on which individual diseases are painted. That is beginning to change. A new generation of biotechnology companies is targeting the cellular and molecular drivers of aging itself, and the capital flowing into the space reflects the shift. The longevity biotech market was valued at $9.86 billion in 2025 and is projected to expand to nearly $29.7 billion by 2034, a 12.84% compound annual growth rate [3]. Cellular therapies, gene editing platforms, and metabolic interventions once confined to academic papers are now moving into late-stage human trials.
One of the most intriguing approaches sits at the intersection of cell therapy and the biology of aging itself. Avaí Bio, Inc. (OTCQB: AVAI), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, announced on April 7, 2026, that it will present the latest data from its a-Klotho anti-aging therapy at the Second Annual Klotho Conference through its joint venture with Austrianova. Representing Avaí Bio, Austrianova, and their joint venture Klothonova, Rahul Pawa, Chief Production Officer at Austrianova, will deliver the presentation during the September conference. The presentation will focus on the production of the longevity protein a-Klotho from genetically modified and encapsulated cells — an approach designed to sustainably restore circulating a-Klotho levels and support potential therapeutic applications in aging and related conditions. For Avaí Bio, Klothonova is the lead anti-aging program, but it is not the only one. The company's second program, Insulinova, targets diabetes — overlapping directly with one of the fastest-growing therapeutic segments in anti-aging medicine, where metabolic health is increasingly viewed as inseparable from biological aging. Both programs rely on the same underlying approach: using encapsulated, genetically modified cell lines to produce therapeutic proteins inside the body, on demand, for extended periods. 
